DELLPHI-301
Regimen
- Experimental
- tarlatamab (DLL3 × CD3 BiTE) 10 mg or 100 mg IV q2w
- Control
- no control (single-agent dose comparison)
Population
Previously treated advanced small-cell lung cancer (median 2 prior lines)
Key finding
ORR 40% (10-mg) vs 32% (100-mg); mPFS 4.9 vs 3.9 mo; 9-mo OS 68% vs 66%; CRS in 51-61%
Source: PMID 37861218
Timeline
Guideline citations
- NCCN SCLC (p.23)
- CSCO SCLC 2025 (p.88)⚠️ OCR source